



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
11)	GAU: 1642
Schneck and O'Herrin		
)	Examiner: Christopher H. Yaen
Serial No.: 09/642,660)	
)	Docket No. 001107.00042
Filed: August 22, 2000)	
<u> </u>	•	

CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES For:

THAT MODIFY IMMUNE RESPONSES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, enclosed is a PTO Form-1449 listing documents for consideration by the Examiner during the prosecution of the subject application.

Please charge our Deposit Account No. 19-0733 in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for the filing fee.

Respectfully submitted,

Dated: July 20, 2006

Lisa M. Hemmendinger

Registration No. 42,653

Customer No. 22907

07/24/2006 HALIII 00000054 190733

09642660

01 FC:1806

180.00 DA

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Stitute for form 1449A/PTO

1

TENT & TRACE

Sheet

MFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

1

 Complete if Known

 Application Number
 09/642,660

 Filing Date
 August 22, 2000

 First Named Inventor
 Schneck

 Group Art Unit
 1643

 Examiner Name
 Christopher H. Yaen

 Attorney Docket Number
 001107,00042

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2		
		Deeths et al., "B7-1-Dependent co-stimulation results in qualitatively and quantitatively different responses by CD4* and CD8*T cells", European Journal of Immunology, Vol. 27, No. 3, 1997, pp 598-608.			
		OERTLI et al., "Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4+lymphocytes invitro", Clinical and Experimental Immunology, Vol. 110, No. 1, October 1997, pp 144-149.			

	The state of the s		
Examiner Signature	·	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.